Bridging radiotherapy before CAR-T therapy in CNS lymphoma.
作者信息
Bacher Ulrike, Pabst Thomas
机构信息
Department of Hematology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
Department of Medical Oncology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
出版信息
Blood Adv. 2024 Oct 8;8(19):5190-5191. doi: 10.1182/bloodadvances.2024013924.
Abstract
摘要
相似文献
1
Bridging radiotherapy before CAR-T therapy in CNS lymphoma.在中枢神经系统淋巴瘤中，在嵌合抗原受体T细胞（CAR-T）疗法之前进行桥接放疗。
Blood Adv. 2024 Oct 8;8(19):5190-5191. doi: 10.1182/bloodadvances.2024013924.
2
Stereotactic radiotherapy and CART for treatment of secondary CNS lymphoma.立体定向放射治疗和嵌合抗原受体T细胞疗法治疗继发性中枢神经系统淋巴瘤。
Leuk Lymphoma. 2024 Jun;65(6):860-863. doi: 10.1080/10428194.2024.2322033. Epub 2024 Mar 7.
3
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.脑室环境可修饰 CAR T 细胞，使其对中枢神经系统和全身淋巴瘤均具有强大的活性。
Cancer Immunol Res. 2021 Jan;9(1):75-88. doi: 10.1158/2326-6066.CIR-20-0236. Epub 2020 Oct 22.
4
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.嵌合抗原受体 T 细胞过继免疫治疗后原发性和继发性中枢神经系统淋巴瘤的神经毒性及处理。
Neuro Oncol. 2023 Dec 8;25(12):2239-2249. doi: 10.1093/neuonc/noad118.
5
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.中枢神经系统桥接放疗在 CAR T 细胞治疗侵袭性 B 细胞淋巴瘤前实现快速细胞减灭。
Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393.
6
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.自体移植后继发性中枢神经系统淋巴瘤的嵌合抗原受体 T 细胞治疗：一例报告。
Medicine (Baltimore). 2021 Nov 5;100(44):e27733. doi: 10.1097/MD.0000000000027733.
7
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.tisagenlecleucel CAR T 细胞疗法治疗中枢神经系统淋巴瘤。
Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18.
8
Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma.通过动脉内注射 NEO100 增强嵌合抗原受体 T 细胞在中枢神经系统淋巴瘤小鼠模型中的脑内进入和治疗活性。
J Neurosurg. 2023 Dec 29;140(6):1549-1557. doi: 10.3171/2023.10.JNS231097. Print 2024 Jun 1.
9
Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.在清除小鼠中枢神经系统淋巴瘤过程中 CAR T 细胞动态的长期体内显微镜观察。
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24275-24284. doi: 10.1073/pnas.1903854116. Epub 2019 Nov 11.
10
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.嵌合抗原受体T细胞疗法治疗继发中枢神经系统受累的套细胞淋巴瘤：一项多中心经验。
Blood Adv. 2024 Jul 9;8(13):3528-3531. doi: 10.1182/bloodadvances.2023012255.
本文引用的文献
1
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas.中枢神经系统桥接放疗在 CAR T 细胞治疗侵袭性 B 细胞淋巴瘤前实现快速细胞减灭。
Blood Adv. 2024 Oct 8;8(19):5192-5199. doi: 10.1182/bloodadvances.2024013393.
2
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.采用靶向 CD19 的嵌合抗原受体（CAR） T 细胞治疗中枢神经系统淋巴瘤的继发疾病。
Cancer Immunol Immunother. 2024 Feb 13;73(3):45. doi: 10.1007/s00262-023-03619-9.
3
Chimeric Antigen Receptor T - Cell Therapy for Large B-Cell Lymphoma Patients with Central Nervous System Involvement, a Systematic Review and Meta-analysis.嵌合抗原受体T细胞疗法治疗中枢神经系统受累的大B细胞淋巴瘤患者：一项系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):e142-e151. doi: 10.1016/j.clml.2023.12.012. Epub 2024 Jan 12.
4
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.无论是否存在中枢神经系统受累，CAR-T细胞疗法在弥漫性大B细胞淋巴瘤患者中显示出相似的疗效和毒性。
Hemasphere. 2023 Nov 30;7(12):e984. doi: 10.1097/HS9.0000000000000984. eCollection 2023 Dec.
5
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.嵌合抗原受体 T 细胞疗法治疗伴有次级中枢神经系统受累的套细胞淋巴瘤的临床疗效和安全性。
Br J Haematol. 2023 Dec;203(5):774-780. doi: 10.1111/bjh.19037. Epub 2023 Aug 16.
6
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.桥接治疗在前体药物 axicabtagene ciloleucel 用于复发/难治性大 B 细胞淋巴瘤之前。
Blood Adv. 2020 Jul 14;4(13):2871-2883. doi: 10.1182/bloodadvances.2020001837.
7
Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.中枢神经系统弥漫性大B细胞淋巴瘤中的抗CD19嵌合抗原受体T细胞
N Engl J Med. 2017 Aug 24;377(8):783-784. doi: 10.1056/NEJMc1704610.
Zotero 插件